Applied Genetic (NASDAQ:AGTC) has been upgraded from Sell to Neutral in a statement by Janney Capital earlier today.
- Updated: September 26, 2016
Janney Capital has upgraded Applied Genetic (NASDAQ:AGTC) from Sell to Neutral in a statement released on 9/26/2016.
On 9/13/2016, BMO Capital Markets released a statement for Applied Genetic (NASDAQ:AGTC) bumped down the target price from $25.00 to $20.00 that suggested an upside of 1.22%.
Boasting a price of $9.12, Applied Genetic (NASDAQ:AGTC) traded 1.56% higher on the day. With the last stock price close down -37.87% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Applied Genetic has recorded a 50-day average of $12.73 and a two hundred day average of $14.65. Trade Volume was up over the average, with 235,844 shares of AGTC changing hands over the typical 159,325
Recent Performance Chart
Applied Genetic has 52 week low of $8.50 and a 52 week high of $21.43 and has a market capitalization of $0.
In addition to Janney Capital reporting its stock price target, a total of 5 brokers have issued a research note on the company. The average stock price target is $31.20 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
Brief Synopsis On Applied Genetic (NASDAQ:AGTC)
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.